At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 180 enrolled

Drug / intervention

GSK Biologicals' AS01B adjuvant +5 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621322

NCT00621322Phase 2Completed

Compare CT.gov

Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.

GlaxoSmithKline·interventional·Posted Feb 22, 2008·Updated Aug 24, 2018

In Brief

A Phase 2 clinical trial evaluating GSK Biologicals' AS01B adjuvant, GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1, and 4 other interventions for Tuberculosis. Completed, enrolled 180 participants across 1 site.

Detailed Summary

This observer blind study will assess the safety and immunogenicity of different formulations of GSK Biologicals' 692342 tuberculosis vaccine in healthy adults aged 18 to 45 years with a positive PPD skin test. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsTuberculosis

CountriesPhilippines

Collaborators--

Timeline

Phase 2CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedFeb 2008

Enrollment StartApr 2008

Primary CompletionApr 2009

TodayJul 2026

First PostedFeb 22, 2008

Enrollment StartApr 3, 2008

Primary CompletionApr 3, 2009

TodayJul 2, 2026

Enrollment to primary: 1 yearPosted 18.4 years ago